Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.50.

A number of analysts have recently issued reports on IMRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research report on Monday, March 9th.

Insider Activity

In other news, Director Peter Feinberg acquired 20,000 shares of Immuneering stock in a transaction dated Monday, January 12th. The shares were purchased at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the transaction, the director owned 135,441 shares of the company’s stock, valued at $589,168.35. This trade represents a 17.32% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Thomas J. Schall acquired 21,645 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were purchased at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the completion of the acquisition, the director owned 74,530 shares in the company, valued at $348,055.10. This represents a 40.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 51,819 shares of company stock worth $234,472 over the last quarter. Corporate insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in IMRX. Sanofi purchased a new stake in shares of Immuneering in the 3rd quarter valued at $18,960,000. Iridian Asset Management LLC CT bought a new position in shares of Immuneering during the 3rd quarter valued at $1,926,000. Monashee Investment Management LLC purchased a new position in Immuneering in the 3rd quarter worth $2,100,000. Blue Owl Capital Holdings LP purchased a new position in Immuneering in the 3rd quarter worth $3,850,000. Finally, Kingsview Wealth Management LLC bought a new stake in Immuneering in the second quarter worth $47,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Price Performance

Shares of IMRX opened at $5.02 on Monday. The firm’s 50 day simple moving average is $4.97 and its 200 day simple moving average is $6.10. The company has a market capitalization of $324.54 million, a P/E ratio of -3.64 and a beta of 0.46. Immuneering has a 1-year low of $1.10 and a 1-year high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Friday, March 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. On average, equities analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.